{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"groups":[{"description":"Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib 600 mg (Fed): Phase II"}],"paramType":"NUMBER","populationDescription":"Phase II safety population","reportingStatus":"POSTED","timeFrame":"Baseline up to death (any cause) (maximum follow up 284 weeks)","title":"Percentage of Participants Who Died Due to Any Cause: Phase II","type":"SECONDARY","unitOfMeasure":"percentage of participants"}